
|Articles|October 24, 2012
Intranasal fentanyl spray benefits compared with oral agents for breakthrough cancer pain
Patients with breakthrough cancer pain (BTCP) may want to consider intranasal fentanyl spray over oral agents to treat their breakthrough pain because of improved onset of analgesia and avoidance of nausea and vomiting, according to a report published online September 25 for The Annals of Pharmacotherapy.
Advertisement
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Most Favored Nation, Direct-to-Consumer Strategies Reshape US Pharma Landscape, Challenging Traditional Care
2
FDA Approves Lumateperone as Adjunct Therapy for Major Depressive Disorder
3
Dementia Increases Risk of COVID-19 Infection, Hospitalization for Older Patients
4
Pharmacists as the Front Line of Vaccine Education and Access
5




















































































































































